{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:56:05Z","timestamp":1792176965593,"version":"4.4.0"},"reference-count":63,"publisher":"Informa UK Limited","issue":"9","license":[{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.2217\/fon-2021-1406","type":"journal-article","created":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T07:08:46Z","timestamp":1639724926000},"page":"1039-1054","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":53,"title":["INSIGHT 2: a Phase II Study of Tepotinib Plus Osimertinib in\n                    <i>MET<\/i>\n                    -Amplified NSCLC and First-Line Osimertinib Resistance"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7329-6995","authenticated-orcid":false,"given":"Egbert","family":"F Smit","sequence":"first","affiliation":[{"name":"Department of Thoracic Oncology,\rNetherlands Cancer Institute,\rAmsterdam,The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7324-7977","authenticated-orcid":false,"given":"Christophe","family":"Dooms","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases &amp; Respiratory Oncology Unit,\rUniversity Hospitals Leuven,\rLeuven,Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8029-4093","authenticated-orcid":false,"given":"Jo","family":"Raskin","sequence":"additional","affiliation":[{"name":"Department of Pulmonology &amp; Thoracic Oncology,\rAntwerp University Hospital (UZA),\rEdegem,Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9674-5554","authenticated-orcid":false,"given":"Ernest","family":"Nadal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Catalan Institute of Oncology,\rL\u2019Hospitalet,\rBarcelona,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4923-4230","authenticated-orcid":false,"given":"Lye M","family":"Tho","sequence":"additional","affiliation":[{"name":"Department of Oncology,\rPantai Hospital,\rKuala Lumpur,Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8554-1185","authenticated-orcid":false,"given":"Xiuning","family":"Le","sequence":"additional","affiliation":[{"name":"Department of Thoracic Head &amp; Neck Medical Oncology, The University of Texas,\rMD Anderson Cancer Center,\rHouston,TX,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5921-7613","authenticated-orcid":false,"given":"Julien","family":"Mazieres","sequence":"additional","affiliation":[{"name":"CHU de Toulouse,\rInstitut Universitaire du Cancer,\rToulouse,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4339-6477","authenticated-orcid":false,"given":"How","family":"S Hin","sequence":"additional","affiliation":[{"name":"Hospital Tengku Ampuan Afzan,\rPahang,Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6576-3349","authenticated-orcid":false,"given":"Masahire","family":"Morise","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine,\rNagoya University Graduate School of Medicine,\rNagoya,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9313-3253","authenticated-orcid":false,"given":"Viola","family":"W Zhu","sequence":"additional","affiliation":[{"name":"University of California Irvine,\rChao Family Comprehensive Cancer Center, Orange,\rCA,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6514-6786","authenticated-orcid":false,"given":"Daniel","family":"Tan","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology,\rNational Cancer Centre Singapore,\rSingapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0760-3990","authenticated-orcid":false,"given":"Kristina","family":"H Holmberg","sequence":"additional","affiliation":[{"name":"EMD Serono Research &amp; Development Institute,\rInc.,\rMA,USA,an affiliate of Merck KGaA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6911-1572","authenticated-orcid":false,"given":"Barbara","family":"Ellers-Lenz","sequence":"additional","affiliation":[{"name":"Department of Biostatistics,\rMerck Healthcare KGaA,\rDarmstadt,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svenja","family":"Adrian","sequence":"additional","affiliation":[{"name":"Global Clinical Development,\rMerck Healthcare KGaA,\rDarmstadt,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Brutlach","sequence":"additional","affiliation":[{"name":"Late Stage Development Operations,\rMerck Healthcare KGaA,\rDarmstadt,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl M","family":"Schumacher","sequence":"additional","affiliation":[{"name":"Global Clinical Development,\rMerck Healthcare KGaA,\rDarmstadt,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki","family":"Karachaliou","sequence":"additional","affiliation":[{"name":"Global Clinical Development,\rMerck Healthcare KGaA,\rDarmstadt,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3611-0258","authenticated-orcid":false,"given":"Yi-Long","family":"Wu","sequence":"additional","affiliation":[{"name":"Guangdong Lung Cancer Institute,\rGuangdong Provincial People\u2019s Hospital &amp; Guangdong Academy of Medical Sciences,\rGuangzhou,China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,12,17]]},"reference":[{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.09.015"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030731"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.28570"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758834009347923"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.09.017"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.12.002"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0337"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612674"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0573-8"},{"key":"e_1_3_7_13_1","unstructured":"European Medicines Agency . Assessment report: tagrisso. (2018). www.ema.europa.eu\/en\/documents\/variation-report\/tagrisso-h-c-4124-ii-0019-epar-assessment-report-variation_en.pdf"},{"key":"e_1_3_7_14_1","volume-title":"IASLC World Conference on Lung Cancer.","author":"Nieva J","year":"2021","unstructured":"Nieva J Taylor A , ServidioLet al. Abstract P48.17: Real-world study of patients with EGFR mutated locally advanced or metastatic non-small cell lung cancer treated with first-line osimertinib. Presented at: IASLC World Conference on Lung Cancer. (2021)."},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13951"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100115"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.01.1103"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027071"},{"key":"e_1_3_7_19_1","article-title":"NCCN Guidelines Version 5.2021","author":"National Comprehensive Cancer Network (NCCN)","year":"2021","unstructured":"National Comprehensive Cancer Network (NCCN) . NCCN Guidelines Version 5.2021. Non-Small Cell Lung Cancer (2021). www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf","journal-title":"Non-Small Cell Lung Cancer"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.10.003"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0777-1"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00121-7"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30154-5"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30084-0"},{"key":"e_1_3_7_25_1","article-title":"VP9-2021: ORIENT-31: phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy","author":"Lu S","year":"2021","unstructured":"Lu S , WuL, JianHet al. VP9-2021: ORIENT-31: phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy. Ann. Oncol. (2021) [In Press].","journal-title":"Ann. Oncol."},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2969"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.02.007"},{"issue":"13","key":"e_1_3_7_28_1","article-title":"Abstract 4897: Detection of MET-mediated EGFR tyrosine kinase inhibitor (TKI) resistance in advanced non-small cell lung cancer (NSCLC): biomarker analysis of the TATTON study","volume":"79","author":"Hartmaier RJ","year":"2019","unstructured":"Hartmaier RJ , HanJ-Y, ChoBCet al. Abstract 4897: Detection of MET-mediated EGFR tyrosine kinase inhibitor (TKI) resistance in advanced non-small cell lung cancer (NSCLC): biomarker analysis of the TATTON study. Cancer Res.79(Suppl. 13), (2019). https:\/\/cancerres.aacrjournals.org\/content\/79\/13_Supplement\/4897","journal-title":"Cancer Res."},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13123096"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2016-0202-RA"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2019.09.003"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.01.1224"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.01.149"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1022"},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100007"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3563"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0759-9"},{"key":"e_1_3_7_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy005"},{"key":"e_1_3_7_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1542"},{"key":"e_1_3_7_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy424.064"},{"key":"e_1_3_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30480-0"},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2310"},{"key":"e_1_3_7_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy483.007"},{"key":"e_1_3_7_44_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1141478"},{"key":"e_1_3_7_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.11.022"},{"key":"e_1_3_7_46_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.722039"},{"key":"e_1_3_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30785-5"},{"key":"e_1_3_7_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.7326"},{"issue":"5","key":"e_1_3_7_49_1","first-page":"S949","article-title":"1239P - ORCHARD osimertinib + savolitinib interim analysis: a biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib","volume":"32","author":"Yu HA","year":"2021","unstructured":"Yu HA , AmbroseH, BaikCet al. 1239P - ORCHARD osimertinib + savolitinib interim analysis: a biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib. Ann. Oncol.32(Suppl. 5), S949\u2013S1039 (2021).","journal-title":"Ann. Oncol."},{"key":"e_1_3_7_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-020-01010-4"},{"key":"e_1_3_7_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00279"},{"key":"e_1_3_7_52_1","unstructured":"Tepmetko (tepotinib) Prescribing Information. Revised. (2021). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214096s000lbl.pdf"},{"issue":"4","key":"e_1_3_7_53_1","first-page":"962","article-title":"The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models","volume":"7","author":"Friese-Hamim M","year":"2017","unstructured":"Friese-Hamim M , BladtF, LocatelliG, StammbergerU, BlaukatA. The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models. Am. J. Cancer Res.7(4), 962\u2013972 (2017).","journal-title":"Am. J. Cancer Res."},{"key":"e_1_3_7_54_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3247"},{"key":"e_1_3_7_55_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2860"},{"key":"e_1_3_7_56_1","volume-title":"IASLC 2021 World Conference on Lung Cancer.","author":"Liam CK","year":"2021","unstructured":"Liam CK , RozilaAhmad A, HsiaTCet al. Tepotinib plus an EGFR TKI in patients with EGFR-mutant NSCLC and resistance to EGFR TKIs due to MET amplification (METamp). Presented at: IASLC 2021 World Conference on Lung Cancer.CO, USAAbstract 47 and poster presentation, 8\u201314 September 2021."},{"key":"e_1_3_7_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-019-00644-6"},{"key":"e_1_3_7_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.07.014"},{"key":"e_1_3_7_59_1","unstructured":"Tagrisso (osimertinib) Prescribing Information. Revised. (2020). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/208065s021lbl.pdf"},{"key":"e_1_3_7_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.1635"},{"key":"e_1_3_7_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.04.033"},{"key":"e_1_3_7_62_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy292"},{"issue":"11","key":"e_1_3_7_63_1","article-title":"Abstract OA 09.03: TATTON Ph Ib expansion cohort: osimertinib plus savolitinib for pts with EGFR-mutant MET-amplified NSCLC after progression on prior EGFR-TKI identification of novel potentially targetable genomic alterations in paired tumors with acquired EGFR TKI Resistance","volume":"12","author":"Ahn M","year":"2017","unstructured":"Ahn M , HanJ, SequistLet al. Abstract OA 09.03: TATTON Ph Ib expansion cohort: osimertinib plus savolitinib for pts with EGFR-mutant MET-amplified NSCLC after progression on prior EGFR-TKI identification of novel potentially targetable genomic alterations in paired tumors with acquired EGFR TKI Resistance. J. Thorac. Oncol.12(11S2), (2017).","journal-title":"J. Thorac. Oncol."},{"key":"e_1_3_7_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01047-5"},{"key":"e_1_3_7_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70057-4"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2021-1406","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T02:43:21Z","timestamp":1719110601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2021-1406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,17]]},"references-count":63,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.2217\/fon-2021-1406"],"URL":"https:\/\/doi.org\/10.2217\/fon-2021-1406","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-10-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}